Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 17,020 Shares of Company Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 17,020 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.53, for a total value of $179,220.60. Following the transaction, the insider owned 152,249 shares in the company, valued at $1,603,181.97. The trade was a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kura Oncology Stock Up 1.9%

NASDAQ KURA traded up $0.20 on Tuesday, reaching $10.81. 1,890,260 shares of the stock traded hands, compared to its average volume of 1,673,937. Kura Oncology, Inc. has a 12 month low of $7.36 and a 12 month high of $13.90. The company has a market cap of $961.66 million, a price-to-earnings ratio of -3.21 and a beta of 0.44. The company has a fifty day moving average price of $11.22 and a 200-day moving average price of $10.15. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. As a group, research analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC acquired a new stake in shares of Kura Oncology during the second quarter worth $1,029,000. WINTON GROUP Ltd increased its position in shares of Kura Oncology by 26.2% in the 2nd quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock valued at $143,000 after acquiring an additional 2,700 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $159,000. IFP Advisors Inc increased its position in shares of Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after acquiring an additional 1,467 shares during the period. Finally, Allworth Financial LP raised its stake in Kura Oncology by 148.4% in the 2nd quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock worth $113,000 after acquiring an additional 6,169 shares during the last quarter.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
• Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
• Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
• Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
• Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Analysts Set New Price Targets

Several research firms have recently commented on KURA. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Wedbush lifted their price target on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.